Scintigraphy of Neuroblastoma with Radioiodinated m-Iodobenzylguanidine

  • J. Farahati
  • S. P. Mueller
  • H. H. Coennen
  • Chr. Reiners


Synthesis of m-iodobenzylguanidine (MIBG), a physiologic norepinephrine analogue, was first accomplished by a group from the University of Michigan in 1980.108 Since then this agent has been demonstrated to be a reliable tool for the diagnosis and localization of various forms of neuroectodermal tumors. In 1980 Wieland et al. described adrenomedullary imaging with MIBG coupled to iodine-131 (131I) in animal studies.108 Since the first report of detection of pheochromocytoma in humans with MIBG93, there have been several reports about the role of this agent in the diagnosis 1,14,26,29,41,48,66,67,82,89 and treatment 4,25,28,46,53,70,73,88,94 of pheochromocytoma and paraganglioma.


MIBG Uptake Malignant Pheochromocytoma MIBG Scintigraphy Iymph Node Advanced Neuroblastoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ackery DM, Tippett PA, Condon BR, Sutton HE, Wyeth P. New approach to the localization of pheochromocytoma: imaging with 131I-metaiodo-benzylguanidine. BMJ 1984;288:1578–1591CrossRefGoogle Scholar
  2. 2.
    Adolph J, Kimmig B. Diagnostik und Therapie neuroektodermaler Tumoren. Radiologe 1989; 29:32–42PubMedGoogle Scholar
  3. 3.
    Altman AJ. Management of malignant solid tumors. In Nathan, Osaki FA (eds): Hematology of Infancy and Childhood (4th ed, vol 2). Philadelphia: Saunders, 1993:1376–1382Google Scholar
  4. 4.
    Beierwaltes WH. New horizons for therapeutic nuclear medicine in 1981. J Nucl Med 1981; 22:549–554PubMedGoogle Scholar
  5. 5.
    Beierwaltes WH. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol 1987;15:188–191PubMedCrossRefGoogle Scholar
  6. 6.
    Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguani-dine. Med Pediatr Oncol 1987;15:163–169PubMedCrossRefGoogle Scholar
  7. 7.
    Bekerman C, Post RB, Pang E. Scintigraphic evaluation of childhood malignancies by 67Ga-citrate. Radiology 1973;127:719–723Google Scholar
  8. 8.
    Berthold F, Burdach S, Kremens B. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the German Pediatric Oncology Society experience. Klin Pediatr 1990;202:262–269CrossRefGoogle Scholar
  9. 9.
    Blake GM, Lewington VJ, Zivanovic MA, Ackery DM. Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine. Eur J Nucl Med 1989;15:618–623PubMedGoogle Scholar
  10. 10.
    Bourliere Najean B, Sues S, Panuel M, et al. Value of MRI and 123I-MIBG scintigraphy in the diagnosis of spinal bone marrow involvement in neuroblastoma in children. Pediatr Radiol 1992; 22:443–446PubMedCrossRefGoogle Scholar
  11. 11.
    Brendel AJ, Guyot M, Jeandot R, et al. Treatment of pheochromocytomas and neuroblastomas with 131I-metaiodobenzylguanidine (MIBG). J Nucl Med 1987;28:627Google Scholar
  12. 12.
    Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098–2103PubMedGoogle Scholar
  13. 12a.
    Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, Bernardi BD, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA (1993) Revisions of International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J Clin Oncol 11:1466–1477PubMedGoogle Scholar
  14. 12b.
    Bruchelt G, Girgert R, Buck J, Wolburg H, Nicthammer D, Treuner J (1988) Cytotoxic effects of m-(I-131)- and m-(I-125)iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK N LO. Cancer Res 48:2993–96Google Scholar
  15. 13.
    Caballero Carpena O, Ferris Tortajada J, Verdeguer Miralies A, Esquembre Menor C, Castel Sanchez V 131I-MIBG scintigraphy in neuroblastoma: a study of 13 cases. Nucl Med 1986;25:A57Google Scholar
  16. 14.
    Cornfeld EJ, Wastie ML, Morgan DA. Malignant paraganglioma of the mediastinum: a further diagnostic and therapeutic use of radiolabeled mIBG. Br J Radiol 1992;65:75–78CrossRefGoogle Scholar
  17. 15.
    Dabasi G, Hernady T, Duffek L, Balint I. Scintigraphic detection of adrenergic tumors and adrenergic dysfunction with 131I-MIBG. Nucl Med 1986;25:A73Google Scholar
  18. 16.
    DeVita VT, Hellman S, Rosenberg SA Solid tumors of childhood. In: Cancer. Principles & Practice of Oncology (3rd ed). Philadelphia: Lippincott, 1989:1624–1631Google Scholar
  19. 16a.
    Dutschka K, Coennen HH (1994) Ungeträgerte Radiosynthese von MIBG and TROPAN-26-Carbonsäure methylester durch nicht-Isotopen, Cu(I)assistierten Halogenaustausch. Nucl Med 33:A11Google Scholar
  20. 17.
    Edeling CJ. Tumor visualization using 67Ga-scintigraphy in children. Radiology 1978; 127: 727–731PubMedGoogle Scholar
  21. 18..
    Englaro EE, Gelfand MJ, Harris RE, Smith HS. 131I-MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology 1992; 182–520Google Scholar
  22. 19.
    Evans AE, Staging and treatment of neuroblastoma. Cancer 1980;45:1799–1802PubMedGoogle Scholar
  23. 20.
    Evans AE, D’Angio GJ, Propert K. Prognostic factors in neuroblastoma. Cancer 1987;59:1853–1859PubMedCrossRefGoogle Scholar
  24. 21.
    Evans AE, D’Angio G, Randolph JA. A proposed staging for children with neuroblastoma: Children’s Cancer Study Group A. Cancer 1971; 27:74–378Google Scholar
  25. 22.
    Farahati J, Eising EG, Mueller SP, Reiners Chr (1994) Sensitivitaet und Spezifitaet der 1–123-MIBG-Szintigraphie in der Diagnose and Verlaufskontrolle bei Kindern mit Neuroblastoma. Zbl Rad 150:37Google Scholar
  26. 22a.
    Farahati J, Müller SP, Eising E, Reiners Chr (1994) Skelettszintigraphie vs. I-123-MIBG-Szintigraphie in der Diagnostik des kindlichen Neuroblastoms. Nucl Med 33:A31Google Scholar
  27. 23.
    Feine U, Mueller-Schauenberg W, Treuner J, Klingebeil T. MIBG labeled with 131I/123I in neuroblastoma diagnosis and follow up treatment with a review of the diagnostic results of the international workshop of pediatric oncology. Med Pediatr Oncol 1987;15:181–187PubMedCrossRefGoogle Scholar
  28. 24.
    Feine U, Treuner J, Niethammer D, et al. Erste Untersuchungen zur szintigraphischen Darstellung von Neuroblastomen mit 131I-meta-Benzyl-guanidin, Mucl Compact 1984;15:23–26Google Scholar
  29. 25.
    Feinendegen LE. Contributions of nuclear medicine to the therapy of malignant tumors. J Cancer Res Clin Oncol 1993; 119:320–322PubMedCrossRefGoogle Scholar
  30. 26.
    Fischer M, Lohmer H. Nuclearmedicine diagnosis of adrenal diseases. Urologe[A] 1993;32:128–132Google Scholar
  31. 27.
    Fischer M, Wehinger H, Kraus C, Ritter J, Schröter W. Treatment of neuroblastoma with 131I-metaiodobenzylguanidine: experience of the Münster/Kassel group. Med Pediatr Oncol 1987; 15:196–199PubMedCrossRefGoogle Scholar
  32. 28.
    Fischer M, Winterberg B, Müller-Rensing R, et al. Nuklearmedizinische Therapie des Pheochro-mozytoms. Nucl Compact 1983;14:172–176Google Scholar
  33. 29.
    Fonseca V, Bouloux PM. Pheochromocytoma and paraganglioma. Baillieres Clin Endocrinol Metab 1993;7:509–544PubMedCrossRefGoogle Scholar
  34. 30.
    Garty I. Pitfalls in the diagnosis of neuroblastoma by 99m-Tc-MDP scintigraphy: a case report. Eur J Nucl Med 1984;9:564–565PubMedGoogle Scholar
  35. 31.
    Garty I, Friedman A, Sandler MP, Kedar A. Neuroblastoma: imaging evaluation by sequential Tc-99m MDP, 131I-MIBG, and 67Ga-citrate studies. ClinNuclMed 1989;14:515–522Google Scholar
  36. 32.
    Garty I, Koren A, Goshen Y. The complementary role of sequential 99mTc -MDP and 67Ga-citrate scanning in the diagnosis and follow up of neuroblastoma. Eur J Nucl Med 1985; 11:224–229PubMedCrossRefGoogle Scholar
  37. 33.
    Garty I, Koren A, Moguilner G. Nearly total absence of pulmonary perfusion with corresponding Tc-99m-MDP and 67Ga-uptake in a patient with mediastinal neuroblastoma. Clin Nucl Med 1985; 10:579–582PubMedCrossRefGoogle Scholar
  38. 34.
    Gasnier B, Roisin MP, Scherman D, et al. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 1986;29: 275–280PubMedGoogle Scholar
  39. 35.
    Geatti O, Shapiro B, Sisson JC. 131I-metaiodoben-zylguanidine (131I-MIBG) scintigraphy for the localization of neuroblastoma: preliminary experience in 10 cases. J Nucl Med 1985;26:736–742PubMedGoogle Scholar
  40. 36.
    Gerrard M, Eden OB, Merrick MV. Imaging and treatment of disseminated neuroblastoma with 131I-meta-iodobenzylguanidine. Br J Radiol 1986; 60:393–395CrossRefGoogle Scholar
  41. 37.
    Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguani-dine uptake by the norepinephrine, dopamine and serotonin transporter. J Nucl Med 1993;34: 1140–1146PubMedGoogle Scholar
  42. 37a.
    Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J (1990) Skeletal assessment in neuroblastoma-Thepitfalls of iodine-123-MIBG scans. J Nucl Med 31:129–134PubMedGoogle Scholar
  43. 38.
    Graham-Pole J, Casar J, Elfenbein G. High dose chemotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:152–158Google Scholar
  44. 39.
    Hadley GP, Rabe E. Scanning with 131I-MIBG in children with solid tumors: an initial appraisal. J Nucl Med 1986;27:620–626PubMedGoogle Scholar
  45. 40.
    Hartmann O, Lumbroso J, Lemerle J, et al. Therapeutic use of 131I-MIBG in neuroblastoma: a phase II study in nine patients. Med Pediatr Oncol 1987;15:205–211PubMedCrossRefGoogle Scholar
  46. 41.
    Hattner RS, Huberty JP, Engelstad BL. Sensitivity and specificity of mIBG scintigraphy for the detection of pheochromocytoma. J Nucl Med 1983; 24:54Google Scholar
  47. 42.
    Heyman S, Evans AE.131I-metaiodobenzylguani-dine in the diagnosis of neuroblastoma. J Nucl Med 1986;27:931–932Google Scholar
  48. 43.
    Hibi S, Todo S, Imashuku S, Miazaki T. l31I-meta-iodobenzylguanidine scintigraphy in patients with neuroblastoma. Pediatr Radiol 1987;17:308–313PubMedCrossRefGoogle Scholar
  49. 44.
    Hoefnagel CA. Diagnostic scintigraphy: updated Amsterdam experience; the Clinical Use of 131I-meta-iodobenzylguanidine for the Diagnosis and Treatment of Neural Crest Tumors. In: Academisch Proefschrift Koninklijke drukkerij Callenbach, Nijkerk, The Netherlands. 1989;98–99Google Scholar
  50. 45.
    Hoefnagel CA, deKraker J, Voute PA, Olmos RA. Preoperative 131I-MIBG therapy of neuroblastoma at diagnosis (“MIBG de novo”). J Nucl Biol Med 1991;35:248–251PubMedGoogle Scholar
  51. 46.
    Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using 131I-metaiodobenzylguanidine. J Nucl Med 1987;28:308–314PubMedGoogle Scholar
  52. 47.
    Hoefnagel CA, Voute PA, deKraker J, Marcuse HR. Total body scintigraphy with 131I-metaio-dobenzylguanidine for detection of neuroblastoma. Diagn Imag Clin Med 1985;54:21–27Google Scholar
  53. 48.
    Horne T, Hawkines LA, Britton KE, et al. Imaging of pheochromocytoma and adrenal medulla with 123I-meta-iodobenzylguanidine. Nucl Med Commun 1984;5:763PubMedCrossRefGoogle Scholar
  54. 49.
    Hutchinson RJ, Sisson JC, Shapiro B, et al. 131I-MIBG treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 1992; 15:226–232PubMedCrossRefGoogle Scholar
  55. 50.
    Iavarone A, Lasorella A, Servidei T, Riccardi R, Mastrangelo R. Uptake and storage of mIBG are frequent neuronal functions of human neuroblastoma call lines. Cancer Res 1993;53:304–309PubMedGoogle Scholar
  56. 51.
    ICRP Publication 53. Biokinetic models, absorbed doses and effective dose equivalents for individual radiopharmaceuticals. Ann ICRP 1987; 18:329–331Google Scholar
  57. 52.
    Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat Rev 1976; 3:61–82PubMedCrossRefGoogle Scholar
  58. 53.
    Jakubowski W, Feltynowski T, Januszewicz W, et al. 131I-meta-iodobenzylguanidine in localization and treatment of pheochromocytoma. Nucl Med Com-mun 1985;6:586Google Scholar
  59. 54.
    Jaques S, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1985;26:539–546Google Scholar
  60. 55.
    Jereb B, Bretsky SS, Vogel R, Helson L. Age and prognosis in neuroblastoma: review of 112 patients younger than 2 years. Am J Pediatr Hematol Oncol 1984;6:233–243PubMedCrossRefGoogle Scholar
  61. 56.
    Johnson RG. Accumulation of biological amines into chromaffin granules: a model for hormonal and neurotransmitter transport. Physiol Rev 1988; 68:232–307PubMedGoogle Scholar
  62. 57.
    Kimmig B, Brandeis WE, Eisenhut M. Scintigraphic diagnosis of neuroblastoma using meta-iodobenzylguanidine. Clin Pediatr 1986; 198:224Google Scholar
  63. 58.
    Kimmig B, Brandeis WE, Eisenhut M. Scintigraphy of neuroblastoma with 131I-MIBG. J Nucl Med 1984;25:773–775PubMedGoogle Scholar
  64. 59.
    Kinnier-Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: a study of 487 cases. BMJ 1974;3:301–307CrossRefGoogle Scholar
  65. 60.
    La Brosse EH, Com-Nougue C. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-metoxy-4-hydroxy phenylacetic acid by 288 patients with neuroblastoma and related neural crest tumor. Cancer Res 1980;40:1995–2001Google Scholar
  66. 61.
    Lashford LS, Hancock JP, Kemshead JT. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer 1991;47:105–109PubMedCrossRefGoogle Scholar
  67. 62.
    Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of 131I-metaiodobenzylguanidine in chemoresistant neuroblastoma; a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol 1992;10:1889–1896PubMedGoogle Scholar
  68. 63.
    Lastoria S, Barile V, Salvatore M. 131I-MIBG scintigraphy for diagnosis of neuroblastoma. Nucl Med 1987;26:40Google Scholar
  69. 64.
    Laug WE, Wiegel SE. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77–82PubMedGoogle Scholar
  70. 65.
    Leikins S, Evans A, Heyen R. The impact of chemotherapy on advanced neuroblastoma: survival of patients diagnosed in 1956, 1962 and 1966–68 in Children’s Cancer Study Group. J Pediatr 1974;84:131–134CrossRefGoogle Scholar
  71. 66.
    Lindberg S, Ernest I, Fjalling M. The value of late images in 131I-meta-iodobenzylguanidine scanning of the adrenal medulla. Eur J Nucl Med 1985; 11:A28Google Scholar
  72. 67.
    Mahlstedt J, Hotze A, Pichl J, Wolf F. Ergebnisse szintigraphischer Untersuchungen mit 131I-meta-iodobenzylguanidine (MIBG) bei Raumforderungen neuroectodermaler Herkunft. Nucl Med 1984;23:257–264Google Scholar
  73. 68.
    Mandel GA, Heyman S. Extraosseous uptake of Tc-99m-MDP in secondary deposits of neuroblastoma. Clin Nucl Med 1986; 11:337–341CrossRefGoogle Scholar
  74. 69.
    Mangner TJ, Tobes MC, Wieland DM, Sisson JC, Shapiro B. Metabolism of 131I-meta-iodobenzyl-guanidine in patients with metastatic pheochromo-cytoma: concise communication. J Nucl Med 1986;27:37--44PubMedGoogle Scholar
  75. 70.
    Marchandise X, Brendel AJ, Charbonnel B, et al. Treatment of malignant pheochromocytoma with 131I-MIBG: results of a French multicenter study. Nucl Med 1987;26:51–52Google Scholar
  76. 71.
    Mastrangelo R. The treatment of neuroblastoma with 131I-MIBG [editorial]. Med Pediatr Oncol 1987;15:157–158PubMedCrossRefGoogle Scholar
  77. 72.
    Maurea S, Cuocolo A, Reynolds JC, et al. 131I-MIBG scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993;34:173–177PubMedGoogle Scholar
  78. 73.
    McEwan AJ, Blake G, Hall VL, Ackery DM. Therapy of malignant pheochromocytoma with 131I-meta-iodobenzylguanidine. Eur J Nucl Med 1985;11:A17CrossRefGoogle Scholar
  79. 74.
    Munkner T. 131I-metaiodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 1985; 15:154–160PubMedCrossRefGoogle Scholar
  80. 75.
    Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent 131I-iodobenzylguanidine (131I-MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672–682PubMedGoogle Scholar
  81. 76.
    Nakajo M, Shapiro B, Glowniak J, Sisson JC, Bierswaltes WH. Inverse relationship between cardiac accumulation of 131I-MIBG and circulating catecholamines in suspected pheochromocytoma. JNucl Med 1984;2:1127–1134Google Scholar
  82. 77.
    Nakajo M, Shapiro B, Sisson JC, Swanson DP, Beierswaltes WH. Salivary gland accumulation of meta-[131I]-iodobenzylguanidine. J Nucl Med 1984;25:2–6PubMedGoogle Scholar
  83. 78.
    Oppedal BR, Storm-Mathisen I, Lie SO. Prognostic factors in neuroblastoma: clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 1988;62:772–780PubMedCrossRefGoogle Scholar
  84. 79.
    Parisi MT, Greene MK, Dykes TM, et al. Efficacy of MIBG as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992;27:768–773PubMedCrossRefGoogle Scholar
  85. 80.
    Parisi MT, Mattay KK, Huberty JP, Hattner RS. Dose related sensitivity of MIBG scanning in detection. Radiology 1992;184:463–467PubMedGoogle Scholar
  86. 81.
    Parisi MT, Sandler ED, Mattay KK, Huberty JP, Hattner RS. MIBG and bone scans: independent, competitive, or redundant in the assessment of neuroblastoma. Radiology 1991;181:222Google Scholar
  87. 82.
    Plewe G, Beyer J, Krause U, et al. Comparison of 131I-meta-iodobenzylguanidine scintigraphy with urinary and plasma catecholamine determinations in the diagnosis of pheochromocytoma. Klin Wochenschr 1985;63:627–630PubMedCrossRefGoogle Scholar
  88. 83.
    Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and MIBG scintigraphy. Radiology 1987;165:89–93PubMedGoogle Scholar
  89. 84.
    Rosen EM, Cassady JR, Frantz CM. Neuroblastoma: The joint Center of Radiation Ther-apy/Dana-Farber Institute/Children’s Hospital experience. J Clin Oncol 1984;2:719–732PubMedGoogle Scholar
  90. 85.
    Rudnik G. ATP driven H+ pumping into intracellular organelles. Annu Rev Physiol 1986;48:403–413CrossRefGoogle Scholar
  91. 86.
    Sawagushi S, Kaneko M, Uchino J. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy: a report from the study groupof Japan. Cancer 1990;66:1879–1887CrossRefGoogle Scholar
  92. 87.
    Seeger RC, Brodeur GM, Sather H. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985;313:1111–1116PubMedCrossRefGoogle Scholar
  93. 88.
    Shapiro B. Imaging of catecholamine-secreting tumors: uses of MIBG in diagnosis and treatment. Baillieres Clin Endocrinol Metab 1993;7:491–507PubMedCrossRefGoogle Scholar
  94. 89.
    Shapiro B, Sisson JC, Eyre P, et al. Diagnostic efficacy of 131I-meta-iodobenzylguanidine and 123I-meta-iodobenzylguanidine in patients with suspected pheochromocytomas. Eur J Nucl Med 1985;11:A28Google Scholar
  95. 90.
    Shulkin BL, Geatti O, Hattner RS, et al. Bilateral testicular neuroblastoma: scintigraphic depiction and therapy with 131I-MIBG. Clin Nucl Med 1992;17:638–642PubMedCrossRefGoogle Scholar
  96. 91.
    Shulkin BL, Shapiro B, Hutchinson RJ.131I-MIBG and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992;33:1735–1740PubMedGoogle Scholar
  97. 92.
    Silber JH, Evans AE, Fridan M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 1991;51:1426–1433PubMedGoogle Scholar
  98. 93.
    Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. NEngl JMed 1981;305:12–17CrossRefGoogle Scholar
  99. 94.
    Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;24:197–206Google Scholar
  100. 95.
    Sisson JC, Wieland DM, Sherman P, et al. Meta-iodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620–1624PubMedGoogle Scholar
  101. 96.
    Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989;49: 2941–2944PubMedGoogle Scholar
  102. 97.
    Stark DD, Moss AA, Brasch RC. Neuroblastoma: diagnostic imaging and staging. Radiology 1983; 148:101–105PubMedGoogle Scholar
  103. 98.
    Tobes MC, Fig LM, Carey J, et al. Alterations of 131I-MIBG biodistribution in an anephric patient: comparison to normal and impaired renal function. J Nucl Med 1989;30:1476–1482PubMedGoogle Scholar
  104. 99.
    Tobes MC, Jaques S, Wieland DM. Effect of uptakeone inhibitors on the uptake of norephinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26:897–907PubMedGoogle Scholar
  105. 100.
    Treuner J, Feine U, Neithammer D. Scintigraphic imaging of neuroblastoma with 131I-iodobenzyl-guanidine. Lancet 1984;1:333–334PubMedCrossRefGoogle Scholar
  106. 101.
    Treuner J, Gerein V, Klingebiele T, et al. MIBG treatment in neuroblastoma; experiences of the Tuebingen/Frankfort group. Prog Clin Biol Res 1988;271:669–678PubMedGoogle Scholar
  107. 102.
    Tsunematsu Y, Koide R, Kobayashi N. Improvement in the treatment of childhood cancer: analysis of survival data from the National Children’s Hospital (1965–1987). Jpn J Clin Oncol 1988;18:309–320PubMedGoogle Scholar
  108. 102a.
    Vaidyanathan G, Zalutsky MR (1993) No-carrier-added synthesis of MIBG. Appl Radiat Isot 44:621–628PubMedCrossRefGoogle Scholar
  109. 103.
    Van Gills AP, Falke THM, van Erkel AR. MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas. Radiographics 1991;11:37–57Google Scholar
  110. 104.
    Velchik MG, Alavi A, Kressel HY, Engelman K. Localization of pheochromocytoma: MIBG, CT, and MRI correlation. J Nucl Med 1989;30: 328–336PubMedGoogle Scholar
  111. 105.
    Wegener OH. Ganzkörpertomograpie (2nd ed). Berlin: Blackwell-Wiss. -Verl. 1992:478–479Google Scholar
  112. 106.
    Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with radioiodinated norephi-nephrine storage analog. J Nucl Med 1981;22:22–31PubMedGoogle Scholar
  113. 107.
    Wieland DM, Brown LE, Tobes MC, et al. Imaging the primate adrenal medulla with [123I] and [131I] metaiodobenzylguanidine: concise communication. J Nucl Med 1981;22:358–364PubMedGoogle Scholar
  114. 108.
    Wieland DM, Wu JL, Brown LE, et al. Radiolabeled adrenergic neuron blocking agent: adrenomedullary imaging with [131I]iodobenzyl-guanidine. J Nucl Med 1980;21:349–353PubMedGoogle Scholar
  115. 109.
    Yeh SDJ, Helson L, Benua RS. Correlation between 131I-MIBG imaging and biological markers in advanced neuroblastoma. Clin Nucl Med 1988;13:46–52PubMedCrossRefGoogle Scholar
  116. 110.
    Young JL, Miller RW Incidence of malignant tumors in US children. J Pediatr 1975;86:254–258PubMedCrossRefGoogle Scholar
  117. 111.
    Zelter PM, Parma AM, Dalton A. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. Lancet 1983;2:361–363CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • J. Farahati
  • S. P. Mueller
  • H. H. Coennen
  • Chr. Reiners

There are no affiliations available

Personalised recommendations